GlassScriptPhysician profile
John J Scaffidi
NPI 1861491193
$2,680.74
in general payments reported to CMS, 2019-2025
31 companies · $476 in 2025
The $476 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $324 · 2021: $246 · 2022: $285 · 2023: $342 · 2024: $351 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,090 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,089.67 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $583.87 | 2019-2025 | Wegovy |
| Abbvie INC. | $452.39 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Ethicon US, LLC | $222.44 | 2019-2020 | |
| Covidien LP | $206.69 | 2019-2020 | |
| Lilly USA, LLC | $206.05 | 2024-2025 | Zepbound |
| Astellas Pharma US INC | $167.13 | 2023-2024 | Veozah |
| Minerva Surgical, INC | $150.00 | 2019 | |
| Mayne Pharma Commercial LLC | $124.57 | 2021-2023 | |
| Inspire Medical Systems, INC. | $48.71 | 2025 | Inspire |
| Therapeuticsmd, INC. | $41.40 | 2019-2020 | |
| Bausch Health US, LLC | $37.51 | 2019 | |
| Pfizer INC. | $37.47 | 2023-2024 | |
| Avion Pharmaceuticals | $37.37 | 2020-2022 | |
| Hologic Sales and Service, LLC | $33.96 | 2019-2023 | Aptima |
| Cumberland Pharmaceuticals, INC. | $32.96 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $32.82 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $29.50 | 2021 | |
| Sumitomo Pharma America, INC. | $28.77 | 2024 | Myfembree |
| Aimmune Therapeutics, INC. | $25.80 | 2025 | Zenpep |
| Becton, Dickinson and Company | $18.40 | 2022 | |
| Omeros Corporation | $17.23 | 2021 | |
| Axonics, INC. | $16.92 | 2023 | Axonics |
| Mylan Pharmaceuticals INC. | $16.21 | 2021 | |
| Lupin INC. | $15.65 | 2019 | |
| Myovant Sciences INC. | $15.23 | 2021 | |
| Fidia Pharma USA INC. | $14.97 | 2023 | Triluron, Hymovis |
| Medtronic, INC. | $14.70 | 2022 | |
| Zimmer Biomet Holdings, INC. | $14.56 | 2020 | |
| Currax Pharmaceuticals LLC | $14.23 | 2025 | Contrave |
| Allergan, INC. | $12.00 | 2019 | |
| Endo Pharmaceuticals INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Scaffidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.